Ondansetrón Aurovitas (Ondansetron)

Ondansetron, the active ingredient in Ondansetrón Aurovitas, is a 5-HT3 receptor antagonist presented as a strength/form for oral use. It treats and prevents nausea and vomiting associated with chemotherapy, radiation therapy, and surgery in adult and pediatric patients.

GNH USA supplies Ondansetrón Aurovitas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Ondansetron is used in the management of nausea and vomiting pathways related to several clinical settings. - Chemotherapy‑induced nausea and vomiting: helps prevent and control acute and delayed episodes. - Radiation‑induced nausea and vomiting: reduces the frequency and severity of symptoms. - Post‑operative nausea and vomiting: decreases the incidence of vomiting after surgery.

Side effects reported with ondansetron are generally mild to moderate and vary by patient population.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - QT interval prolongation: cardiac rhythm changes detectable on ECG. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: agitation, hyperreflexia, tremor when combined with serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Severe constipation or intestinal obstruction. - Vision changes: blurred vision or visual disturbances.

When using ondansetron, clinicians should consider several safety aspects. - Cardiac monitoring: assess baseline ECG in patients with known cardiac disease. - Electrolyte balance: correct hypokalaemia or hypomagnesemia before use. - Drug interactions: review concomitant medications that affect QT interval. - Pregnancy: weigh benefits against potential risks; use only if clearly needed. - Breastfeeding: monitor infant for possible effects if mother continues therapy. - Store at ambient temperature: keep below 25°C, in original packaging, protected from moisture.

Ondansetron may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amiodarone: combined use can markedly increase QT prolongation risk. - Certain anti‑arrhythmics (e.g., sotalate, procainamide): additive effect on cardiac repolarisation. - Serotonergic agents (e.g., tramadol, linezolid): may precipitate serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antifungal azoles (ketoconazole, fluconazole): may increase ondansetron plasma levels. - Macrolide antibiotics (erythromycin, clarithromycin): modest effect on QT interval. - CYP3A4 inhibitors (cimetidine, grapefruit juice): can raise drug exposure. - Digoxin: potential for altered serum concentrations. - Metoclopramide: overlapping anti‑emetic mechanisms may require dose adjustment.